UT Southwestern Medical Center researchers have discovered that increasing the levels of a protein called BACH2 makes ...

Scientists at the Icahn School of Medicine at Mount Sinai have developed an experimental immunotherapy that takes an ...

Although rheumatologists consider chimeric antigen receptor T-cell therapy “potentially transformative,” nearly 70% remain ...

The Food and Drug Administration (FDA) has approved Breyanzi ® (lisocabtagene maraleucel; liso-cel) for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) ...

The FDA's breakthrough therapy designation facilitates accelerated development and regulatory review for therapies showing ...

This interview discusses how BCMA-directed CAR T-cell therapy in multiple myeloma may be more effective when administered ...

A personal reflection on the promise and limits of CAR T therapy—its breakthroughs, failures, scientific bottlenecks, and what must change to truly save more lives.

Editing CAR T cells to produce inflammatory cytokines helps them enter solid tumors and promote cancer killing.

Q: My partner and I disagree about whether our dog June should ride loose in the back seat of the car or sit in the front ...

Not all cholesterol is bad! High-density lipoprotein (HDL), or “good cholesterol,” acts like the cleanup crew, sweeping away ...

CAR T cell therapy has transformed blood cancer treatment, but success in solid tumors remains limited by major challenges such as on-target/off-tumor toxicity, poor tumor infiltration, and an ...